title: Mixed response to ipilimumab in a melanoma patient with brain metastases: case report and review of the literature.
abstract: Management of patients suffering from metastatic malignant melanoma and brain metastasis remains challenging in routine clinical practice. The inhibitory anti-CTLA-4 antibody ipilimumab has recently been approved as second-line therapeutic option for melanoma patients. Increasing evidence suggests distinct therapeutic activity on central nervous system metastases, although this continues to be actively debated. Here, we present the case of a patient suffering from metastatic melanoma, including symptomatic brain metastasis, who showed a partial response to ipilimumab in extracranial tumor manifestations, while the disease was progressing intracranially. Subsequently, intracranial disease progression could be managed by local irradiation. An overview of currently available literature on the efficacy of ipilimumab in melanoma patients with central nervous system metastases is provided.
authors.affiliation: Department of Internal Medicine 3, Center of Integrated Oncology (CIO) Cologne-Bonn, University Hospital of Bonn, Bonn, Jena University Hospital, Jena, Germany.
authors.forename: Georg
authors.initials: G
authors.lastname: Feldmann
authors.forename: Peter
authors.initials: P
authors.lastname: Brossart
authors.forename: Matthias
authors.initials: M
authors.lastname: Zipfel
authors.forename: Marie
authors.initials: M
authors.lastname: von Lilienfeld-Toal
keywords: Brain metastases; Ipilimumab; Melanoma; Survival